We are seeking world-class partners to help us bring advanced therapies to patients in need.
Janux is always looking for opportunities to partner with world class organizations to maximize the potential of our platform and develop effective therapies for patients with life-threatening conditions.
In December 2020, Janux entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr two product candidates that are distinct from those in our internally developed pipeline. Merck has exercised its right to select both collaboration targets related to next generation TCE immunotherapies for the treatment of cancer.
If you are interested in exploring partnership opportunities with us, please visit our contact page and submit an information request form.